

The Dawn of *in vivo* Tau Imaging

Victor L. Villemagne^{ab}, Shozo Furumoto^c, Christopher C. Rowe^a and Nobuyuki Okamura^d

AUTHOR INFORMATION

- a. Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, VIC, 3084, Australia.
- b. The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC, 3010, Australia.
- c. Cyclotron and Radioisotope Center, Tohoku University, Sendai, 980-8578, Japan
- d. Department of Pharmacology, Tohoku University School of Medicine, Sendai, 980-8575, Japan.

Corresponding author:

Victor L. Villemagne, MD,
Department of Nuclear Medicine and Centre for PET, Austin Health
145 Studley Rd, Heidelberg, VIC, 3084, AUSTRALIA
Tel: +61 3 9496 3321
victorlv@unimelb.edu.au (email)

REFERENCES

1. Mohorko N and Bresjanac M: Tau Protein And Human Tauopathies: An Overview. *Zdrav Vestn* 2008; 77:35–41.
2. McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, et al.: Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. *J Neuropathol Exp Neurol* 2009; 68:709-735.
3. Komori T: Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease. *Brain Pathol* 1999; 9:663-679.
4. Arriagada PV, Growdon JH, Hedley-Whyte ET and Hyman BT: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. *Neurology* 1992; 42:631-639.
5. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al.: Imaging beta-amyloid burden in aging and dementia. *Neurology* 2007; 68:1718-1725.
6. Price JL, McKeel DW, Jr., Buckles VD, Roe CM, Xiong C, Grundman M, et al.: Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. *Neurobiol Aging* 2009; 30:1026-1036.
7. Delacourte A, Sergeant N, Wattez A, Maurage CA, Lebert F, Pasquier F, et al.: Tau aggregation in the hippocampal formation: an ageing or a pathological process? *Exp Gerontol* 2002; 37:1291-1296.
8. Goedert M and Jakes R: Mutations causing neurodegenerative tauopathies. *Biochim Biophys Acta* 2005; 1739:240-250.
9. von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow EM, et al.: Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. *J Biol Chem* 2001; 276:48165-48174.
10. Gotz J, Gladbach A, Pennanen L, van Eersel J, Schild A, David D, et al.: Animal models reveal role for tau phosphorylation in human disease. *Biochim Biophys Acta* 2010; 1802:860-871.
11. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al.: Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. *Science* 2007; 316:750-754.
12. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, et al.: Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. *Proc Natl Acad Sci U S A* 2005; 102:227-231.
13. Wischik CM, Edwards PC, Lai RY, Roth M and Harrington CR: Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. *Proc Natl Acad Sci U S A* 1996; 93:11213-11218.
14. Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM, et al.: Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. *J Neurosci* 2010; 30:13861-13866.
15. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al.: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. *Ann Neurol* 2004; 55:306-319.
16. Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Harada R, Mulligan RS, Kudo T, et al.: The Challenges of Tau Imaging. *Future Neurol.* 2012; 7:409-421.
17. Mukaetova-Ladinska EB, Harrington CR, Roth M and Wischik CM: Biochemical and anatomical redistribution of tau protein in Alzheimer's disease. *Am J Pathol* 1993; 143:565-578.
18. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al.: Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. *Jama* 2000; 283:1571-1577.
19. Villemagne VL, Fodero-Tavoletti MT, Pike KE, Cappai R, Masters CL and Rowe CC: The ART of Loss: A β Imaging in the Evaluation of Alzheimer's Disease and other Dementias. *Mol Neurobiol* 2008; 38:1-15.

20. Pike VW: PET radiotracers: crossing the blood-brain barrier and surviving metabolism. *Trends Pharmacol Sci* 2009; 30:431-440.
21. Taghavi A, Nasir S, Pickhardt M, Heyny-von Haussen R, Mall G, Mandelkow E, et al.: N'-benzylidene-benzohydrazides as novel and selective tau-PHF ligands. *J Alzheimers Dis* 2011; 27:835-843.
22. Kemp S, Storey L, Storey J, Rickard J, Harrington C and Wischik C, *Ligands for aggregated tau molecules*. , 2010: International patent 2010/034982.
23. Honson NS, Jensen JR, Darby MV and Kuret J: Potent inhibition of tau fibrillization with a multivalent ligand. *Biochem Biophys Res Commun* 2007; 363:229-234.
24. Szardenings AK, Zhang W, Kolb HC, Cashion DK, Chen G, Kasi D, et al., *Imaging Agents for Detecting Neurological Disorders*, 2011, Siemens Medical Solutions USA, Inc.: US Patent 2011/0182812 A1.
25. Kudo Y, Susuki M, Suemoto T, Okamura N, Shiomitsu T and Shimazu H, *Quinoline derivative as diagnostic probe for disease with tau protein accumulation*, 2006: U.S. Patent 7,118,730.
26. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al.: Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. *Am J Geriatr Psychiatry* 2002; 10:24-35.
27. Nelson LD, Siddarth P, Kepe V, Scheibel KE, Huang SC, Barrio JR, et al.: Positron emission tomography of brain beta-amyloid and tau levels in adults with Down syndrome. *Arch Neurol* 2011; 68:768-774.
28. Small GW, Kepe V, Siddarth P, Ercoli LM, Merrill DA, Donoghue N, et al.: PET Scanning of Brain Tau in Retired National Football League Players: Preliminary Findings. *Am J Geriatr Psychiatry* 2013; 21:138-144.
29. Kepe V, Bordelon Y, Boxer A, Huang SC, Liu J, Thiede FC, et al.: PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. *J Alzheimers Dis* 2013; 36:145-153.
30. Bresjanac M, Smid LM, Vovko TD, Petric A, Barrio JR and Popovic M: Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl]ethylidene) malononitrile labels prion plaques in vitro. *J Neurosci* 2003; 23:8029-8033.
31. Kepe V, Ghetti B, Farlow MR, Bresjanac M, Miller K, Huang SC, et al.: PET of brain prion protein amyloid in Gerstmann-Straussler-Scheinker disease. *Brain Pathol* 2010; 20:419-430.
32. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al.: Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls. *Neuron* 2013; 79:1094-1108.
33. Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al.: [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. *Alzheimers Dement* 2013.
34. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al.: Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. *J Alzheimers Dis* 2013; 34:457-468.
35. Mintun M, Schwarz A, Joshi A, Shcherbinin S, Chien D, A. E, et al.: Exploratory Analyses Of Regional Human Brain Distribution of The PET Tau Tracer F18-Labeled T807 (AV-1541) in Subjects With Normal Cognitive Function or Cognitive Impairment Thought to be due to AD. *Alzheimer & Dementia* 2013; 9:P842.
36. Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, et al.: Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808. *J Alzheimers Dis* 2014; 38:171-184.
37. Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, et al.: 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. *Brain* 2011; 134:1089-1100.
38. Harada R, Okamura N, Furumoto S, Tago T, Maruyama M, Higuchi M, et al.: Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. *Eur J Nucl Med Mol Imaging* 2013; 40:125-132.
39. Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, et al.: In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. *Eur J Nucl Med Mol Imaging* 2014; (doi: 10.1007/s00259-013-2681-7).